1. Carvedilol significantly reduced mortality from cardiovascular causes and recurrent non-fatal MI.
2. While carvedilol treatment was associated with a 23% relative risk reduction in all-cause mortality, this did not reach statistical significance.
3. These findings are consistent with previous trials exploring the benefits of beta-blockers in managing acute MI.